Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded a decrease of -8.53%. However, over the last six months, the performance has been weaker by 74.12%. The price of CRDF decreased -8.10% over the last 30 days. And in the last five days, it has surged by 13.43%.
Cardiff Oncology Inc experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $6.42 on 03/25/24, while the lowest price for the same period was registered at $1.44 on 02/05/24.
52-week price history of CRDF Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cardiff Oncology Inc’s current trading price is -38.16% away from its 52-week high, while its distance from the 52-week low is 175.69%. The stock’s price range during this period has varied between$1.44 and $6.42. The Cardiff Oncology Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.49 million for the day, a figure considerably lower than their average daily volume of 2.14 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cardiff Oncology Inc (CRDF) has experienced a quarterly rise of 32.78% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 264.08M and boasts a workforce of 32 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.14, with a change in price of +1.76. Similarly, Cardiff Oncology Inc recorded 1,547,624 in trading volume during the last 100 days, posting a change of +79.64%.
CRDF’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CRDF stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.02.
CRDF Stock Stochastic Average
As of today, Cardiff Oncology Inc’s raw stochastic average for the last 50 days stands at 50.60%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 43.90%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 22.15% and 13.73%, respectively.
